Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care-Reference-Cited by-同舟云学术

Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care

Published:2019-09-28 Issue:2 Volume:49 Page:294-303
ISSN:0929-5305
Container-title:Journal of Thrombosis and Thrombolysis
language:en
Short-container-title:J Thromb Thrombolysis

Author:

Gulilat Markus,Keller Denise,Linton Bradley,Pananos A. Demetri,Lizotte Daniel,Dresser George K.,Alfonsi Jeffrey,Tirona Rommel G.,Kim Richard B.,Schwarz Ute I.^ORCID

Funder

Ontario Ministry of Research, Innovation and Science

Canadian Institutes of Health Research

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,Hematology

Link

http://link.springer.com/content/pdf/10.1007/s11239-019-01962-2.pdf

Reference56 articles.

1. Byon W, Garonzik S, Boyd RA, Frost CE (2019) Apixaban: a clinical pharmacokinetic and pharmacodynamic review. Clin Pharmacokinet. https://doi.org/10.1007/s40262-019-00775-z

2. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365:981–992. https://doi.org/10.1056/NEJMoa1107039

3. Connolly SJ, Eikelboom J, Joyner C, Diener H-C, Hart R, Golitsyn S, Flaker G, Avezum A, Hohnloser SH, Diaz R, Talajic M, Zhu J, Pais P, Budaj A, Parkhomenko A, Jansky P, Commerford P, Tan RS, Sim K-H, Lewis BS, Van Mieghem W, Lip GYH, Kim JH, Lanas-Zanetti F, Gonzalez-Hermosillo A, Dans AL, Munawar M, O’Donnell M, Lawrence J, Lewis G, Afzal R, Yusuf S (2011) Apixaban in patients with atrial fibrillation. N Engl J Med 364:806–817. https://doi.org/10.1056/NEJMoa1007432

4. Barnes GD, Lucas E, Alexander GC, Goldberger ZD (2015) National trends in ambulatory oral anticoagulant use. Am J Med 128:1300-5 e2. https://doi.org/10.1016/j.amjmed.2015.05.044

5. Gulilat M, Tang A, Gryn SE, Leong-Sit P, Skanes AC, Alfonsi JE, Dresser GK, Henderson SL, Rose RV, Lizotte DJ, Teft WA, Schwarz UI, Tirona RG, Kim RB (2017) Interpatient variation in Rivaroxaban and Apixaban plasma concentrations in routine care. Can J Cardiol 33:1036–1043. https://doi.org/10.1016/j.cjca.2017.04.008

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association between genotypes ofABCB1, ABCG2andCYP3A5and the risk of atrial fibrillation;2024-07-16

2. [Artículo traducido] Exploración del impacto de la farmacogenética en la medicina personalizada: una revisión sistemática;Farmacia Hospitalaria;2024-06

3. Pharmacogenetic considerations in therapy with novel antiplatelet and anticoagulant agents;Pharmacogenetics and Genomics;2024-02-19

4. Exploring the impact of pharmacogenetics on personalized medicine: A systematic review;Farmacia Hospitalaria;2024-02

5. Does amiodarone impact on apixaban levels? The effect of amiodarone on apixaban level among Thai patients with non-valvular Atrial Fibrillation;PLOS ONE;2024-01-19